RK

Raj Kumar Jain

Active Director Director DIN 10069737
DIN 10069737 First appointment Mar 2023 Primary industry Wood
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2023
Shareholding value •••• Premium profile

About Raj Kumar Jain

Data last updated:

Raj Kumar Jain is a Director at Reydis Pharmaceuticals Private Limited (since 2023). The company operates in Wood. Reydis Pharmaceuticals Private Limited reported revenue of ₹9.9 Lakh (FY 2025).

DIN 10069737
Primary Designation Director
Industry Wood
First Appointment 13 Mar 2023
Oldest Company Age 3 yrs
Largest company Reydis Pharmaceuticals Private Limited · ₹9.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director13 Mar 20232023₹9.9 Lakh (FY 2025)Active

Board colleagues of Raj Kumar Jain

Directorship timeline

Open interactive timeline →
Reydis Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Raj Kumar Jain

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Raj Kumar Jain

Raj Kumar Jain currently holds 1 directorship: Reydis Pharmaceuticals Private Limited (Director, since 13 Mar 2023, revenue ₹9.9 Lakh (FY 2025)).

Raj Kumar Jain was first appointed on 13 Mar 2023 as Director at Reydis Pharmaceuticals Private Limited.

The current boards of Raj Kumar Jain's companies include Deepak Kumar Jain (Reydis Pharmaceuticals Private Limited), Saurabh Sharma (Reydis Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available